
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical demonstrated a positive financial trajectory, with full year 2025 revenue increasing to approximately $71.6 million, marking an 11% growth over the previous year and aligning with the company's revised guidance. The company exhibited an improvement in net cash use, reducing it sequentially from $6.2 million to approximately $5.1 million, indicating enhanced financial management. Additionally, management's guidance for 2026 revenue between $80 million and $85 million points to a potential resurgence in commercial momentum, driven by deeper market penetration and integration of its product offerings.
Bears say
Avita Medical's financial outlook is concerning due to a revision in revenue expectations, leading to a lowered valuation target from $14.00 to $10.00. The company reported a net loss of $11.6 million, maintaining a per-share loss of $0.38, which is slightly improved from $0.44 per share in the previous year, but still highlights ongoing challenges. Additionally, the focus on a single product, the RECELL system, and limited international marketing efforts raise further concerns about long-term growth potential and sustainability.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares